Published:
Wyeth Names Michael Kamarck President, Technical Operations & Product Supply
MADISON, N.J., Nov. 20 /PRNewswire-FirstCall/ -- Wyeth (NYSE: WYE) today
announced that Michael Kamarck, Ph.D., 57, has been promoted to President,
Technical Operations & Product Supply (TO&PS). Dr. Kamarck will be
responsible for all aspects of technical operations and product supply for
Wyeth, including its Pharmaceutical, BioPharma, Vaccine, Consumer Healthcare
and Nutritional units. He succeeds Charles Portwood, 58, who has been
appointed to the new role of Executive Vice President, TO&PS Operational
Excellence. Both positions will report to Joseph Mahady, President, Wyeth
Pharmaceuticals.
"Dr. Kamarck brings strong leadership as well as superb technical and
scientific skills to this critical role. He will continue the transformation
of our TO&PS organization as we supply medicines of exceptional quality to our
customers and patients," says Mr. Mahady.
He joined Wyeth in 2001 and over the next six years successfully led the
expansion of Wyeth's global biotechnology manufacturing network. In 2007, Dr.
Kamarck was promoted to Executive Vice President, TO&PS where he was
responsible for biotechnology and pharmaceutical operations at 13
international sites and for process development of the late-stage pipeline.
Dr. Kamarck began his career in biotechnology and pharmaceutical research
for Bayer AG. Before joining Wyeth, he was promoted to Senior Vice President
of Operations for the newly formed Bayer Biologicals.
He graduated from Oberlin College and received his Ph.D. in Biochemistry
from the Massachusetts Institute of Technology. From 1979 to 1982, Dr.
Kamarck was a Fellow of the Leukemia Society of America at Yale University.
He is the author of more than 50 peer-reviewed publications and eight issued
patents.
Mr. Portwood joined Wyeth in 2001 as President, Global Supply Chain, Wyeth
Pharmaceuticals. Through his experience and leadership, he has guided a major
transformation of the TO&PS organization.
"Charlie has taken our TO&PS organization to a whole new level of
competency and performance," says Mr. Mahady. "He has been instrumental in
creating this succession plan and in building a depth of talent in the TO&PS
leadership team. We are pleased he will remain an integral part of the Wyeth
organization. We are counting on him to support improvement and
standardization efforts across the Wyeth manufacturing network."
Wyeth is one of the world's largest research-driven pharmaceutical and
health care products companies. It is a leader in the discovery, development,
manufacturing and marketing of pharmaceuticals, vaccines, biotechnology
products, nutritionals and non-prescription medicines that improve the quality
of life for people worldwide. The Company's major divisions include Wyeth
Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.
SOURCE Wyeth
Copyright © 2009, PRNewswire
newsblaze
Copyright © 2009, NewsBlaze,
Daily NewsTags: ,HEA,MTC,BIO,PER,NJ-Wyeth-Names-Pres
_ _Is your favorite bookmark site missing?
Ask for it.
Search News
Daily News
